[{"address1": "2929 7th Street", "address2": "Suite 105", "city": "Berkeley", "state": "CA", "zip": "94710", "country": "United States", "phone": "510 982 6030", "website": "https://cariboubio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.", "fullTimeEmployees": 158, "companyOfficers": [{"maxAge": 1, "name": "Dr. Rachel E. Haurwitz Ph.D.", "age": 38, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1986, "fiscalYear": 2023, "totalPay": 979083, "exercisedValue": 0, "unexercisedValue": 486940}, {"maxAge": 1, "name": "Dr. Steven B. Kanner Ph.D.", "age": 65, "title": "Chief Scientific Officer", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 669310, "exercisedValue": 0, "unexercisedValue": 447452}, {"maxAge": 1, "name": "Ms. Barbara G. McClung Esq., J.D.", "age": 69, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 669310, "exercisedValue": 0, "unexercisedValue": 402144}, {"maxAge": 1, "name": "Mr. Ryan  Fischesser", "title": "Interim Principal Accounting Officer, Interim Principal Financial Officer & Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Poon", "title": "Vice President of Operations & Information Technology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy P. Kelly M.B.A.", "age": 55, "title": "Chief Technology Officer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Figueroa C.F.A.", "title": "Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Reigin  Zawadzki", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ruhi A. Khan M.B.A.", "age": 49, "title": "Chief Business Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 573900, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 5, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.59, "open": 1.62, "dayLow": 1.61, "dayHigh": 1.775, "regularMarketPreviousClose": 1.59, "regularMarketOpen": 1.62, "regularMarketDayLow": 1.61, "regularMarketDayHigh": 1.775, "beta": 2.263, "forwardPE": -0.8111906, "volume": 1347537, "regularMarketVolume": 1347537, "averageVolume": 1417345, "averageVolume10days": 1482170, "averageDailyVolume10Day": 1482170, "bid": 1.64, "ask": 1.72, "bidSize": 200, "askSize": 200, "marketCap": 152128544, "fiftyTwoWeekLow": 1.5, "fiftyTwoWeekHigh": 8.33, "priceToSalesTrailing12Months": 13.257389, "fiftyDayAverage": 2.046, "twoHundredDayAverage": 2.541025, "currency": "USD", "enterpriseValue": -57558228, "floatShares": 81578916, "sharesOutstanding": 90552704, "sharesShort": 9797621, "sharesShortPriorMonth": 7417636, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.1082, "heldPercentInsiders": 0.10037, "heldPercentInstitutions": 0.62487, "shortRatio": 6.47, "shortPercentOfFloat": 0.113400005, "impliedSharesOutstanding": 90552704, "bookValue": 3.105, "priceToBook": 0.5410628, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -148120000, "trailingEps": -1.66, "forwardEps": -1.99, "enterpriseToRevenue": -5.016, "enterpriseToEbitda": 0.365, "52WeekChange": -0.69186044, "SandP52WeekChange": 0.25443196, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "CRBU", "underlyingSymbol": "CRBU", "shortName": "Caribou Biosciences, Inc.", "longName": "Caribou Biosciences, Inc.", "firstTradeDateEpochUtc": 1627047000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f11f6be1-a9a3-3c9c-bdb1-a1f42c197bdb", "messageBoardId": "finmb_272189231", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.68, "targetHighPrice": 26.0, "targetLowPrice": 3.0, "targetMeanPrice": 12.5, "targetMedianPrice": 11.5, "recommendationKey": "none", "numberOfAnalystOpinions": 8, "totalCash": 228178000, "totalCashPerShare": 2.52, "ebitda": -157800000, "totalDebt": 26641000, "quickRatio": 7.178, "currentRatio": 7.383, "totalRevenue": 11475000, "debtToEquity": 9.474, "revenuePerShare": 0.128, "returnOnAssets": -0.25142, "returnOnEquity": -0.43598998, "freeCashflow": -78726872, "operatingCashflow": -124109000, "revenueGrowth": -0.914, "operatingMargins": -16.66897, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-02"}]